Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

608
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
608
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

660
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
660
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

577
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
577
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

864
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
864
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

577
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
577
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

976
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
976

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nudging provider adoption of clinical decision support: study protocol for a stepped-wedge cluster randomized, hybrid type III trial of an electronic health record-agnostic pulmonary embolism risk tool.

Implementation science : IS·2026
Same author

Two decades of diagnostic safety research: advances, challenges, and next steps.

Diagnosis (Berlin, Germany)·2025
Same author

Evaluation of CTPA Ordering for Pulmonary Embolisms by Patient Race and Ethnicity.

Academic emergency medicine : official journal of the Society for Academic Emergency Medicine·2025
Same author

Assessment of PredictSURE IBD Assay in a Multinational Cohort of Patients With Inflammatory Bowel Disease.

United European gastroenterology journal·2025
Same author

Snowball Group Usability Testing for Rapid and Iterative Multisite Tool Development: Method Development Study.

JMIR formative research·2025
Same author

Effect of a behavioral nudge on adoption of an electronic health record-agnostic pulmonary embolism risk prediction tool: a pilot cluster nonrandomized controlled trial.

JAMIA open·2024
Same journal

Low-cost dynamic fascial traction using serial Bogota bag tightening in open abdomen management: A prospective randomized study.

World journal of gastrointestinal pharmacology and therapeutics·2026
Same journal

Predictors of clinically significant complications after stoma reversal: A prospective analytical study.

World journal of gastrointestinal pharmacology and therapeutics·2026
Same journal

Beyond intestinal failure: Expanding therapeutic frontiers of glucagon-like peptide-2 in gastrointestinal disease.

World journal of gastrointestinal pharmacology and therapeutics·2026
Same journal

Metabolic dysfunction-associated steatotic liver disease and obstructive sleep apnea: A cohort analysis of prevalence and hepatic outcomes.

World journal of gastrointestinal pharmacology and therapeutics·2026
Same journal

Current approaches to disease severity and therapy effectiveness assessment in patients with inflammatory bowel disease.

World journal of gastrointestinal pharmacology and therapeutics·2026
Same journal

Beyond gluten-free diet: Novel therapeutic frontiers in celiac disease armamentarium.

World journal of gastrointestinal pharmacology and therapeutics·2026
See all related articles

Related Experiment Video

Updated: Mar 2, 2026

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
09:44

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis

Published on: October 14, 2025

544

Combination therapy for inflammatory bowel disease.

Keith S Sultan1, Joshua C Berkowitz1, Sundas Khan1

  • 1Keith S Sultan, Department of Medicine, Division of Gastroenterology, Hofstra Northwell School of Medicine, Manhasset, NY 11030, United States.

World Journal of Gastrointestinal Pharmacology and Therapeutics
|May 24, 2017
PubMed
Summary
This summary is machine-generated.

Combination therapy (CT) with biologics and immunomodulators improves outcomes in inflammatory bowel disease. Further research is needed on optimal duration, alternative agents, and risks like lymphoma.

Keywords:
AdalimumabAzathioprineCrohn’s diseaseInflammatory bowel diseaseInfliximabMethotrexateUlcerative colitisVedolizumab

More Related Videos

Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice
07:34

Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice

Published on: December 16, 2021

3.3K
Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

13.0K

Related Experiment Videos

Last Updated: Mar 2, 2026

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
09:44

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis

Published on: October 14, 2025

544
Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice
07:34

Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice

Published on: December 16, 2021

3.3K
Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

13.0K

Area of Science:

  • Gastroenterology and Immunology
  • Pharmacology and Therapeutics

Background:

  • Biologic therapies (e.g., infliximab, adalimumab) are standard for inflammatory bowel disease (IBD).
  • Early research suggested combination therapy (CT) of biologics with immunomodulators (e.g., azathioprine) could enhance efficacy and reduce immunogenicity.
  • Landmark trials (SONIC, UC SUCCESS) showed CT superiority over monotherapy in treatment-naïve moderate-to-severe Crohn's disease and ulcerative colitis.

Purpose of the Study:

  • To review the current evidence on the risks and benefits of combination therapy in IBD.
  • To identify areas requiring further research regarding CT protocols and patient populations.

Main Methods:

  • Literature review of clinical trials and observational studies on combination therapy in IBD.
  • Analysis of data pertaining to efficacy, pharmacokinetics, immunogenicity, and safety profiles of CT.

Main Results:

  • CT with infliximab and azathioprine demonstrated superior remission rates in treatment-naïve patients.
  • Unanswered questions remain regarding CT in non-naïve patients, optimal duration, and effectiveness with alternative agents.
  • Potential risks of CT include opportunistic infections and an increased risk of lymphoma.

Conclusions:

  • Combination therapy offers significant benefits for select IBD patients, particularly in treatment-naïve moderate-to-severe disease.
  • Further research is crucial to define optimal CT strategies, including agent selection, duration, and risk mitigation for diverse patient groups.
  • Personalized treatment strategies balancing efficacy and safety are essential for managing IBD with combination therapy.